Cellectis
Created in 1999
- BETA
Trend leader (A+)
Existing signals make this entity one of the most dynamic startups Social networks
4,549 43,278Activities
Technologies
Entity types
Location
8 Rue de la Croix Jarry, 75013 Paris, France
Paris
France
Employees
Scale: 51-200
Estimated: 232
SIREN
428859052Engaged corporates
19
6 8Added in Motherbase
5 years, 3 months ago
deeptech Value proposition
Cellectis is developing life-changing product candidates to target and eradicate cancer cells.
Cellectis is a global clinical-stage biopharmaceutical company. Pioneers and innovators in our field, our mission is to develop innovative treatments for patients with unmet medical needs.
With 25 years of expertise, we have the best-in-class gene editing platform focusing on immuno-oncology, and gene therapy. Through our efficient and precise TALEN® technology, we create allogeneic CAR-T cells capable of recognizing and combating cancer cells.
Today, our two* clinical programs target patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and non-Hodgkin lymphoma (NHL).
We are fully integrated and a leader in end-to-end gene editing, allogeneic CAR T-cell companies. With our in-house manufacturing, we control our gene and cell therapy process from start to finish with starting materials produced in Paris (France) and CAR-T therapy products created in Raleigh, NC (USA).
We also have several ongoing strong collaborations, based on our TALEN® technology, with leading cell & gene therapy companies, including our recent partnership with AstraZeneca, to develop new product candidates in oncology, immunology, and treatment of rare diseases.
At Cellectis, we are committed to a cure.
Cellectis headquarters are in Paris, France, with additional locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).
To find out more about us, visit our website: www.cellectis.com. To learn more about our community guidelines, visit: http://www.cellectis.com/en/social-media-guidelines/
Follow our other social media accounts: @cellectis on LinkedIn on X (formerly Twitter) .
(*) On November 4, 2024, Cellectis decided to focus its current development efforts on the BALLI-01 and NATHALI-01 studies and therefore to deprioritize the development of UCART123.
TALEN® is a registered trademark owned by the Cellectis Group.
Gene editing, Life sciences, Oncology, T-Cell therapies, genome engineering, allogeneic, and off-the-shef CART therapiesOriginal language
Cellectis is developing life-changing product candidates to target and eradicate cancer cells.
Cellectis is a global clinical-stage biopharmaceutical company. Pioneers and innovators in our field, our mission is to develop innovative treatments for patients with unmet medical needs.
With 25 years of expertise, we have the best-in-class gene editing platform focusing on immuno-oncology, and gene therapy. Through our efficient and precise TALEN® technology, we create allogeneic CAR-T cells capable of recognizing and combating cancer cells.
Today, our two* clinical programs target patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and non-Hodgkin lymphoma (NHL).
We are fully integrated and a leader in end-to-end gene editing, allogeneic CAR T-cell companies. With our in-house manufacturing, we control our gene and cell therapy process from start to finish with starting materials produced in Paris (France) and CAR-T therapy products created in Raleigh, NC (USA).
We also have several ongoing strong collaborations, based on our TALEN® technology, with leading cell & gene therapy companies, including our recent partnership with AstraZeneca, to develop new product candidates in oncology, immunology, and treatment of rare diseases.
At Cellectis, we are committed to a cure.
Cellectis headquarters are in Paris, France, with additional locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).
To find out more about us, visit our website: www.cellectis.com. To learn more about our community guidelines, visit: http://www.cellectis.com/en/social-media-guidelines/
Follow our other social media accounts: @cellectis on LinkedIn on X (formerly Twitter) .
(*) On November 4, 2024, Cellectis decided to focus its current development efforts on the BALLI-01 and NATHALI-01 studies and therefore to deprioritize the development of UCART123.
TALEN® is a registered trademark owned by the Cellectis Group.
Home | Cellectis
Cellectis is a clinical-stage biopharmaceutical company developing the Next-Generation CAR T-Cells to Cure Cancer
https://www.cellectis.com/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 Orange Telecoms, Law Practice, Telecommunications | Orange Telecoms, Law Practice, Telecommunications | Other 27 Feb 2020 | | |
 La Tribune Media, Newspapers | La Tribune Media, Newspapers | Other 27 Jun 2022 | | |
 Centre-Val de Loire Region National and local authorities, Government Administration | Centre-Val de Loire Region National and local authorities, Government Administration | Other 13 Dec 2019 | | |
 Illumina For Startups Startup accelerator & VC, Biotechnology, Biotechnology Research | Illumina For Startups Startup accelerator & VC, Biotechnology, Biotechnology Research | Other 26 Jun 2015 | | |
 Greater Paris University Hospitals - AP-HP Health, Hospitals and Health Care | Greater Paris University Hospitals - AP-HP Health, Hospitals and Health Care | Other 27 Feb 2020 | | |
 Biogen Biotechnology, Biotechnology Research | Biogen Biotechnology, Biotechnology Research | Other 13 Apr 2021 | | |
 Merck Group Pharmaceutical, Biotechnology, Pharmaceutical Manufacturing | Merck Group Pharmaceutical, Biotechnology, Pharmaceutical Manufacturing | Other 12 Dec 2019 | | |
 AstraZeneca Pharmaceutical, Pharmaceutical Manufacturing | AstraZeneca Pharmaceutical, Pharmaceutical Manufacturing | Other 9 Nov 2017 9 May 2024 | | |
 Catapult.org National and local authorities, Civic & Social Organization | Catapult.org National and local authorities, Civic & Social Organization | Other 11 Feb 2019 | | |
 Nasdaq Finance, Financial Services | Nasdaq Finance, Financial Services | Other 29 Jul 2016 | | |